TransCode Therapeutics, Inc. Common Stock (RNAZ) News

Latest headlines that mention RNAZ, newest first · each headline opens the original publisher

RNAZ quote

Last price: $1.71
Day change: -3.64%
Next earnings: 2026-11-13

Quote & chart Expected move Insider trading IV rank history

RNAZ headlines

latest coverage

Not much coverage yet. RNAZ has appeared in only a few headlines lately; new stories show up here as publishers cover it.

Investing.com 1d ago

TransCode presents phase 1a trial data for cancer therapy

General T3RNAZ

Seeking Alpha News 1mo ago

TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript

General T2RNAZ

Investing.com 1mo ago

Transcode Therapeutics announces CFO resignation and interim appointment

General T3RNAZ

Seeking Alpha 1mo ago

TransCode Therapeutics CFO retires

General T2RNAZ

Seeking Alpha News 4mo ago

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

General T2RNAZ

Investing.com 4mo ago

Form DEF 14A TRANSCODE THERAPEUTICS For: 2 June

General T3RNAZ

RNAZ news alerts

Get an alert by email or push when a new headline mentions RNAZ.

More news

News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.